// App-Quantinova.ai

5053 : Genome-wide analysis of metastases to reveal association of pathway activation with abiraterone acetate/prednisone (AA/P) primary resistance and cell cycle proliferation pathway activation with response duration in metastatic castrate resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Manish Kohli

Principal Investigators

  • Scott Dehm

  • David W. Hillman

  • Hugues Sicotte

  • Michael Gormley

  • Vipul Bhargava

  • Weimin Li

  • Winston Tan

  • Henry C. Pitot

  • Thai Huu Ho

  • Brian Addis Costello

  • Alan H. Bryce

  • Ye Zhenqing

  • Peter T Vedell

  • Poulami Barman

  • Rafael E. Jimenez

  • Rachel Carlson

  • Liguo Wang

Medical Centers

  • Mayo Clinic, Rochester, MN

  • University of Minnesota, Minneapolis, MN

  • Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN

  • Janssen Research and Development, LLC, Spring House, PA

  • Johnson & Johnson, Spring House, PA

  • Mayo Clinic, Jacksonville, FL

  • Mayo Clinic, Scottsdale, AZ

  • Department of Oncology, Mayo Clinic, Rochester, MN

Locations

  • United States

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

  • Prednisone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01953640

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved